---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-088722"
form_type: "8-K"
ticker: "ZURA"
cik: "0001855644"
company_name: "Zura Bio Ltd"
filed_at: "2024-08-13T23:59:59+00:00"
generated_at: "2026-05-31T09:50:26.955706+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Zura Bio reports Q2 2024 net loss of $12.7M, cash of $188.4M; plans Phase 2 starts for tibulizumab

## Summary
- Net loss of $12.7M ($0.17/share) vs $44.9M ($1.31/share) in Q2 2023; reduction driven by prior-year acquisition costs.
- Cash, cash equivalents and investments of $188.4M as of June 30, 2024, including $112.5M from April private placement; sufficient through 2027.
- Tibulizumab Phase 2 study in systemic sclerosis expected to start in Q4 2024; Phase 2 in hidradenitis suppurativa expected in Q2 2025.
- CEO Robert Lisicki appointed in April 2024; founding CEO Dr. Someit Sidhu remains on Board.
- R&D expenses were $5.5M in Q2 2024, down from $28.2M in Q2 2023 due to prior-year tibulizumab acquisition from Lilly.

## SEC filing metadata
- accession: 0001104659-24-088722
- form_type: 8-K
- ticker: ZURA
- cik: 0001855644
- company_name: Zura Bio Ltd
- filed_at: 2024-08-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1855644/000110465924088722/0001104659-24-088722-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1855644/000110465924088722/tm2411301d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-088722
- JSON: https://secwatch.observer/filing/0001104659-24-088722.json
- Plain text: https://secwatch.observer/filing/0001104659-24-088722.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.